Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients;Corrélation des concentrations plasmatiques de résistine avec l'obésité et l'insulinorésistance chez des diabétique de type 2.

Diabetes and Metabolism

Volumn 36, Issue 6, 2010, Pages 443-449

  Gharibeh, M Y ^a   Al Tawallbeh, G M ^a   Abboud, M M ^b   Radaideh, A ^c   Alhader, A A ^a   Khabour, O F ^a  

^a JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^b MUTAH UNIVERSITY   (Jordan)

^c Princess Basma Teaching Hospital   (Jordan)

Author keywords

Insulin resistance; Jordan; Obesity; Resistin; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; RESISTIN; TRIACYLGLYCEROL; UREA;

ADULT; AGE; ARTICLE; BLOOD PRESSURE; BODY FAT DISTRIBUTION; BODY MASS; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPOSITY; ADULT; AGED; AGING; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; JORDAN; MALE; MIDDLE AGED; OBESITY; RESISTIN; RISK FACTORS;

EID: 78650006092     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.05.003     Document Type: Article

References (39)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl. 1):S55-60.
2. Bloomgarden Z.T. Obesity and diabetes. Diabetes Care 2000, 23:1584-1590.
3. Duman B.S., Turkoglu C., Gunay D., Cagatay P., Demiroglu C., Buyukdevrim A.S. The interrelationship between insulin secretion and action in type 2 diabetes mellitus with different degrees of obesity: evidence supporting central obesity. Diabetes Nutr Metab 2003, 16:243-250.
4. Athyros V.G., Tziomalos K., Karagiannis A., Anagnostis P., Mikhailidis D.P. Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets 2010, 11:122-135.
5. Stejskal D., Adamovska S., Bartek J., Jurakova R., Proskova J. Resistin - concentrations in persons with type 2 diabetes mellitus and in individuals with acute inflammatory disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2003, 147:63-69.
6. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009, 10:96-107.
7. Lazar M.A. Resistin- and obesity-associated metabolic diseases. Horm Metab Res 2007, 39:710-716.
8. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., Watson W., Kerr K., Jones R., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
9. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010, 44:25-36.
10. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149:331-335.
11. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
12. Hasegawa G., Ohta M., Ichida Y., Obayashi H., Shigeta M., Yamasaki M., et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol 2005, 42:104-109.
13. Heilbronn L.K., Rood J., Janderova L., Albu J.B., Kelley D.E., Ravussin E., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 2004, 89:1844-1848.
14. Laudes M., Oberhauser F., Schulte D.M., Freude S., Bilkovski R., Mauer J., et al. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010, 42:268-273.
15. Burnett M.S., Devaney J.M., Adenika R.J., Lindsay R., Howard B.V. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 2006, 91:64-68.
16. Ajlouni K., Khader Y.S., Batieha A., Ajlouni H., El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications 2008, 22:317-324.
17. Hume R. Prediction of lean body mass from height and weight. J Clin Pathol 1966, 19:389-391.
18. Hosker J.P., Matthews D.R., Rudenski A.S., Burnett M.A., Darling P., Bown E.G., et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia 1985, 28:401-411.
19. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
20. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.
21. Fujinami A., Obayashi H., Ohta K., Ichimura T., Nishimura M., Matsui H., et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 2004, 339:57-63.
22. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003, 88:6098-6106.
23. Lee J.H., Chan J.L., Yiannakouris N., Kontogianni M., Estrada E., Seip R., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 2003, 88:4848-4856.
24. Yannakoulia M., Yiannakouris N., Bluher S., Matalas A.L., Klimis-Zacas D., Mantzoros C.S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88:1730-1736.
25. Schaffler A., Buchler C., Muller-Ladner U., Herfarth H., Ehling A., Paul G., et al. Identification of variables influencing resistin serum levels in patients with type 1 and type 2 diabetes mellitus. Horm Metab Res 2004, 36:702-707.
26. Gabriely I., Ma X.H., Yang X.M., Atzmon G., Rajala M.W., Berg A.H., et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process?. Diabetes 2002, 51:2951-2958.
27. Vozarova de Courten B., Degawa-Yamauchi M., Considine R.V., Tataranni P.A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 2004, 53:1279-1284.
28. Al-Harithy R.N., Al-Ghamdi S. Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann Saudi Med 2005, 25:283-287.
29. Al-Daghri N., Chetty R., McTernan P.G., Al-Rubean K., Al-Attas O., Jones A.F., et al. Serum resistin is associated with C-reactive protein & LDL cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 2005, 4:10.
30. Vendrell J., Broch M., Vilarrasa N., Molina A., Gomez J.M., Gutierrez C., et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004, 12:962-971.
31. Rajala M.W., Qi Y., Patel H.R., Takahashi N., Banerjee R., Pajvani U.B., et al. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004, 53:1671-1679.
32. Valsamakis G., McTernan P.G., Chetty R., Al Daghri N., Field A., Hanif W., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53:430-434.
33. Smith S.R., Bai F., Charbonneau C., Janderova L., Argyropoulos G. A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003, 52:1611-1618.
34. Ellington A.A., Malik A.R., Klee G.G., Turner S.T., Rule A.D., Mosley T.H., et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007, 50:708-714.
35. Axelsson J., Bergsten A., Qureshi A.R., Heimburger O., Barany P., Lonnqvist F., et al. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 2006, 69:596-604.
36. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 2005, 111:932-939.
37. Ohmori R., Momiyama Y., Kato R., Taniguchi H., Ogura M., Ayaori M., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379-380.
38. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2-11.
39. Khabour OF, Mesmar FS, Alatoum MA, Gharaibeh MY, Alzoubi KH. Associations of polymorphisms in adiponectin and leptin genes with men's longevity. Aging Male 2010 (doi: 10.3109/13685531003657800).